United Kingdom Analysis

Pages

Industry Trend Analysis - Generic Competition To Continue To Hurt AstraZeneca Revenues - JUNE 2017

AstraZeneca's shareholders will keep a close eye on the company's management's strategy, the late-stage R&D pipeline and newly launched USD1.1bn cost-cutting plan. While investor focus on company activity has been strong since the decline in sales of the company's top blockbuster drugs - Nexium lost patent protection in the US in February 2015 and Crestor experienced patent expiry in...

READ FULL ARTICLE

Pages